Glinskii Victoria G, Glinsky Gennadi V
The School of Public Health, The University of California at Berkeley, Berkeley, California, USA.
Cell Cycle. 2008 Aug;7(15):2278-85. doi: 10.4161/cc.6476. Epub 2008 Jun 23.
With the completion of the Human Genome Project in May 2006, genetic testing for every American is rapidly becoming a reality. As the advanced technology fuels the path towards personalized medicine, genetic nondiscrimination legislation follows closely behind. It seems that the 2007 Genetic Information Nondiscrimination Act (GINA) will finally pass through both chambers of Congress and will be signed by the President, but questions remain. On May 1, 2008, the House passed GINA by a vote of 414 to 1. Why is this the year that genetic nondiscrimination legislation could finally become the reality? Is this the beginning of a new relationship between science and policy, where policy is finally catching up? We examine the answers to these questions through a look at the history of genetic nondiscrimination legislation and where it stands today, including arguments for and against the bill. We conclude by discussing how we can achieve a future of safe personalized medicine for the populous, which would require continuous productive interactions between policymakers and scientists.
随着2006年5月人类基因组计划的完成，对每个美国人进行基因检测正迅速成为现实。随着先进技术推动个性化医疗的发展道路，基因非歧视立法也紧随其后。2007年的《基因信息非歧视法案》（GINA）似乎最终将在国会两院通过，并将由总统签署，但问题依然存在。2008年5月1日，众议院以414票对1票通过了GINA。为什么今年基因非歧视立法最终可能成为现实？这是科学与政策之间新关系的开始吗，即政策终于赶上来了？我们通过审视基因非歧视立法的历史及其目前的状况来探讨这些问题的答案，包括支持和反对该法案的论点。我们最后讨论如何为广大民众实现安全的个性化医疗的未来，这将需要政策制定者和科学家之间持续的富有成效的互动。
